Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 200 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intraocular Melanoma Clear all
Terminated Phase 1 Interventional

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

NCT05341349
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Ocular Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Stereotactic Radiosurgery, Tumor Treating Fields Therapy
Biological · Radiation · Procedure
Lead sponsor
Emory University
Other
Eligibility
22 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

NCT03408587
View directory record Official record
Conditions
Uveal Melanoma, Liver Metastases
Interventions
CVA21, Ipilimumab
Biological
Lead sponsor
Viralytics
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Miami Beach, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema

NCT00441662
View directory record Official record
Conditions
Melanoma
Interventions
Sub-Tenon triamcinolone 40mg
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2007 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Treatment With Intravitreal Avastin for Large Uveal Melanomas

NCT00596362
View directory record Official record
Conditions
Uveal Melanoma
Interventions
AVASTIN
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

NCT01814046
View directory record Official record
Conditions
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated No phase listed Observational

Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy

NCT00346372
View directory record Official record
Conditions
Ocular Melanoma
Interventions
Not listed
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

NCT00738361
View directory record Official record
Conditions
Intraocular Melanoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 4, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

NCT01979523
View directory record Official record
Conditions
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Trametinib, Uprosertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 4, 2026, 2:42 AM EDT
Not listed Phase 1 Interventional

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

NCT03068624
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Interventions
Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide, Ipilimumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 4, 2026, 2:42 AM EDT
Active, not recruiting No phase listed Observational

A Prospective Natural History Study in Uveal Melanoma

NCT04588662
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 4, 2026, 2:42 AM EDT
Active, not recruiting Not applicable Interventional

Psychoeducation for Uveal Melanoma

NCT06075589
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Education for Intervention, Best Practice
Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated Phase 1 Interventional

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05576077
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
TBio-4101, Pembrolizumab
Biological · Drug
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Irvine, California • Hollywood, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 4, 2026, 2:42 AM EDT
Recruiting Phase 2 Interventional

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

NCT06070012
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Tebentafusp
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated Phase 1 Interventional

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

NCT03865212
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Choroid Melanoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 4, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

Adjuvant Tebentafusp in High Risk Ocular Melanoma

NCT06246149
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Tebentafusp
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 1Phase 2 Interventional

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

NCT00005815
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
temozolomide, thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

NCT00680225
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
Ranibizumab injection and TTT - ICG based
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Hamden, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 4, 2026, 2:42 AM EDT
Terminated Phase 1 Interventional

FHD-286 in Subjects With Metastatic Uveal Melanoma

NCT04879017
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
FHD-286
Drug
Lead sponsor
Foghorn Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

NCT01460810
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
1000CsK Silicon Oil Tamponade
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant and Adjuvant Checkpoint Blockade

NCT02519322
View directory record Official record
Conditions
Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Relatlimab, Therapeutic Conventional Surgery
Biological · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

NCT01200238
View directory record Official record
Conditions
Ocular Melanoma
Interventions
STA-9090
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 4, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

NCT00031733
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, sargramostim, tyrosinase peptide, alum adjuvant, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 4, 2026, 2:42 AM EDT
Completed No phase listed Observational

Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma

NCT01253759
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
TTT + ICG-based PDT
Procedure
Lead sponsor
New England Retina Associates
Other
Eligibility
18 Years to 95 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Hamden, Connecticut
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 4, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

NCT05907954
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
10
States / cities
Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 4, 2026, 2:42 AM EDT